The lawsuit, filed by Levi & Korsinsky, LLP, targets the period between January 13, 2025, and January 29, 2026. The market volatility was triggered by the release of REMAIN-1 Midpoint Cohort data, which revealed that patients treated with Revita experienced a 4.5% weight regain. This figure contrasted sharply with previous company assertions from September 2025 that suggested superior weight-loss results following the cessation of GLP-1 therapy.
In section Releases
Fractyl Health Faces Class Action After 75% Share Price Collapse
Fractyl Health investors are facing a massive devaluation of their holdings after the company’s share price plummeted nearly 75% over two trading sessions. A newly filed securities class action alleges the company misled shareholders regarding the efficacy of its Revita DMR treatment during the REMAIN-1 clinical trial.
Following the January 29, 2026 announcement, Fractyl Health shares fell 68.03%, dropping from $1.83 to $0.585. A secondary decline occurred the following day after analysts reacted to the news, pushing the stock down to $0.46. The complaint contends that management failed to disclose critical site-level issues, specifically that one of the six study locations lacked a robust dietary counseling program, which skewed the reported efficacy data. Investors who purchased stock during the class period have until October 20, 2026, to seek appointment as lead plaintiff in the Southern District of New York.
Comments (0)
No comments yet. Be the first!